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ABSTRACT. The risk of developmental of total parenteral
nutrition (TPN)-associated cholestatic jaundice in neonates
receiving intravenous hyperalimentation is high. Numerous
factors have been cited as contributing to TPN cholestasis;
however, the exact etiology remains obscure. This retrospective
study was undertaken in order to identify any factors which
might contribute to this syndrome.
The hospital records of 172 neonates requiring TPN for a
minimum of 1 week were reviewed. In addition, a subgroup of
32 infants requiring TPN for a minimum of 7 weeks was also
examined. Cholestasis was defined as a direct serum bilirubin
greater than 2.0 mg/dl during the course of TPN therapy.
Significant factors for the development of cholestasis in both
groups (n = 172, = 32) included: number of operations (2.56
vs. 1.08, p = 0.0000), the number of days the patients received
antibiotics (40.3 vs 12.9, p = 0.0000), and delayed start of
enteral feedings (33.8 vs 14.1, p = 0.0000).
Fifteen of the 32 patients who received TPN for at least 7
weeks did not develop cholestasis. In this subgroup (n = 32),
there were no differences in birth weight, gestational age, days
from birth to the start of TPN, or respiratory distress between
those who developed cholestasis and those who remained an-
icteric. In contrast, there were significant differences between
the cholestasis and noncholestasis groups in number of opera-
tions (13 vs 6, p = 0.0407), and days until enteral feedings were
started (33.1 vs 18.9, p = 0.0289).
This study suggests that the factor(s) contributing to the
development of TPN-associated cholestasis are likely multifac-
torial. There appears to be a direct correlation between increas-
ing severity of cholestatic jaundice and duration of TPN. This
review does add a new parameter to the various causative
factors suggested, namely the number of operative procedures.
This new variable could be related to the stress of surgery itself
or to the repeated administration of anesthetic agents. (Journal
of Parenteral and Enteral Nutrition 13:586-589, 1989)
Despite attempts by numerous investigators to deter-
mine the etiology of total parenteral nutrition (TPN)-
associated hepatic dysfunction, the exact cause of TPN-
induced cholestasis remains obscure. The risk of devel-
oping TPN-associated cholestatic jaundice in neonates
requiring intravenous (iv) hyperalimentation remains
high.1-3 Although this condition usually resolves with
time after discontinuation of the TPN,4-’ a small per-
centage of cases remain intractable’ and/or progress to
severe hepatic dysfunction and death.9-11
Merritt,12 Seashore,13 and Farrell and Balistreri,14 in
separate reviews have cited the various factors thought
to contribute to TPN cholestasis. These include the
following: 1) clinical components: low-birth weight, pre-
maturity, duration of TPN, immature enterohepatic cir-
culation, intestinal microflora, bacterial sepsis; and 2)
metabolic components: energy overload, increased levels
of toxic bile salts, enteral starvation, amino acid com-
position of infusate, excess or deficiency of specific amino
acids, and mineral/trace element excesses or deficiencies.
This study was designed to examine pertinent demo-
graphic, clinical, and nutritional components in a large
population of neonates requiring TPN in order to refute
or confirm findings reported in earlier studies and to
determine if additional factors contribute to this syn-
drome.
METHODS
The hospital records of 172 neonates requiring TPN
for a minimum of 7 days wee retrospectively reviewed.
Descriptive data as well as total input an output for each
24-hr period the infant received intravenous nutrition
were recorded. A subpopulation of these patients (n =
32) received TPN for a minimum of 7 weeks. These
patients were additionally analyzed as a separate group
since the length of administration of the TPN was quite
long.
All patients were begun on a peripherally administered
TPN program of glucose, crystalline amino acids, and
either a safflower oil emulsion (Liposyn, Abbott Labo-
ratories) or a soybean oil emulsion (Intralipid, Baxter
Laboratories). Patients requiring long-term TPN
(greater than 3-4 weeks were switched to centrally ad-
ministered TPN). The solutions for centrally adminis-
tered TPN consisted of 25% glucose and 3.5% crystalline
amino acids, whereas the peripheral regimen consisted
of 12.5% glucose and 2.5% crystalline amino acids. The
fat emulsion provided a maximum of 40% of the daily
caloric input for both the centrally and peripherally
administered TPN.
Variables analyzed included: birth weight, gestational
age at birth, number of operations, days on iv antibiotics,
serum biochemistries, and mean weekly caloric intake
divided into the following categories: lipid calories/kg,
protein calories/kg, carbohydrate calories/kg, total cal-
ories/kg, and nonprotein calories/kg.
Cholestasis was defined as a direct bilirubin greater
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than 2.0 mg/dl during the course of TPN therapy. Other
cause of an elevated serum bilirubin were excluded in all
patients analyzed (n = 172).
Statistical analysis was performed using the student’s
t-test and chi-square analysis with p-values less than
0.05 considered statistically significant.
RESULTS
There were 92 boy (53.5%) and 80 girl infants (46.5%)
in the study cohort. A total of 74 patients (43.0%) under-
went a minimum of one major surgical procedure. Of the
172 patients studied, 26 ( 15.1 % ) developed cholestasis.
There were no significant differences in birth weight
(p = 0.6089) or gestational age (p = 0.7594) between
those infants developing cholestasis and those who did
not. However, the number of operations (2.56 in the
cholestasis group us 1.08 in the noncholestasis group) as
well as the number of days the patients received intra-
venous antibiotics (40.3 in the cholestasis group us 12.9
in the noncholestasis group) were significantly different
(p = 0.0000 in each category). In addition, the infants
who developed cholestasis waited 33.8 days (mean) before
the start of enteral feedings compared to 14.1 days
(mean) for the patients without cholestasis (p = 0.0000)
(Table I).
The underlying diseases and clinical course in the
subgroup of newborns (n = 32) who received TPN for a
minimum of 7 consecutive weeks is similar. Seventeen
of these patients developed cholestasis within this time
frame (group 1), while 15 remained anicteric (group 2).
There were major anomalies in these patients in the
gastrointestinal, cardiac, pulmonary, and nervous sys-
tems.
The variables which proved significant for the devel-
opment of cholestasis in the subgroup of patients who
received TPN for a minimum of 7 weeks were as follows:
number of patients undergoing surgery, (13 us 6, p =
0.0407) and days from birth to the start of enteral feed-
ings (33.1 us 18.9, p = 0.0289) in the cholestasis and
noncholestasis groups, respectively. The actual number
of operations (2.69 us 1.33) and the number of days
receiving iv antibiotics (44.6 us 26.4) were close to being
statistically significantly different (p = 0.0632 and p =
0.0602, respectively). In contrast, there were no signifi-
cant differences between the cholestasis and noncholes-
tasis groups in birth weight, gestational age, and the
number of days from birth to start of TPN (Table II).
In addition, in this sub-group of newborns, there were
no significant differences between those with cholestasis
(group 1) and those without cholestasis (group 2) with
TABLE I
Variables related to TPN-induced cholestasis (n = 172)
respect to the following TPN components expressed as
the mean weekly value per kilogram administered: pro-
tein calories (Fig. 1), glucose calories (Fig. 2), lipid calo-
ries (Fig. 3), total calories (Fig. 4) or nonprotein calories
(Fig. 5).
The development of cholestasis with increasing dura-
tion of TPN is presented in Figure 6. Cholestasis did not
develop in any patients who received TPN for only 1
week. In contrast, 100% (all seven) of the patients who
received TPN for a minimum of 12 weeks developed
cholestatic jaundice.
The mean value of the highest direct bilirubin levels
for the patients who received TPN for 1 to 6 weeks (n =
9), 7 to 10 weeks (n = 9), and more than 11 weeks (n =
8) is presented in Figure 7. There is an increasing mean
TABLE II
Variables related to onset of cholestasis in patients receiving TPN for 7
consecutive weeks (n = 32)
FIG. 2. Glucose calories (mean) administered per week.
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FIG. 3. Lipid calories (mean) administered per week.
FIG. 4. Total calories (mean) administered per week.
.. --..-
FIG. 5. Nonprotein calories (mean) administered per week.
bilirubin level with increasing duration of TPN, 4.21 ±
1.63, 4.91 ± 1.44, and 5.56 ± 1.61, respectively.
DISCUSSION
The reported incidence of TPN-associated cholestasis
in infants receiving iv nutrition varies from 7 to 42 % .15° 16
In this study, 15.1% of the total population examined
developed cholestatic jaundice, defined as a direct bili-
rubin equal to or greater than 2.0 mg% during the course
of iv nutrition. As previously reported, sepsis&dquo; and num-
ber of operations 1,2 were risk factors for the development
of this condition in our series. However, low birth
weight/8, 19 prematurity,20 respiratory distress,15 or quan-
tity of protein ’21 glucose,16 lipid,22 and total calories in-
fused were not significant risk factors associated with
TPN-cholestasis in this series ( us most of the others
reported in the literature). The previously reported re-
FIG. 6. Cholestasis and noncholestasis patient distribution us weeks
of TPN therapy.
.. --..- -.....
FIG. 7. Highest direct bilirubin levels (mean) during TPN therapy.
lationships probably reflect the fact that more newborns
who are premature, have low birth weight and who
experience respiratory distress require TPN in compar-
ison with other neonates and probably undergo more
operations than other newborns. Most importantly, this
study argues against the likelihood of the TPN solution
per se contributing to cholestasis,’ since both the group
1 and group 2 infants received similar solutions for three
and one-half times the minimal interval (2 weeks) con-
sidered as necessary for the development of choles-
tasis,23> 24 an observation which has not been previously
reported.
This study, like others, suggests that the factor(s)
contributing to the development of TPN-associated cho-
lestasis are likely multifactorial, and as yet, not com-
pletely determined. There appears to be a direct corre-
lation between increasing severity of cholestatic jaundice
(increasing serum levels of direct bilirubin) and duration
of TPN. However, this study does add a new parameter
to the various causative factors suggested, namely the
number of operative procedures. This new variable could
be related to the stress of surgery itself or to the repeated
administration of anesthetic agents. If one further pos-
tulates that an immature hepatobiliary system is initially
subjected to the stress of birth, followed shortly there-
after by the stress of surgery, then it is easy to imagine
the development of hepatic dysfunction and resulting
cholestasis.
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